Khadka Sundar, Pandit Roshan, Dhital Subhash, Baniya Jagat Bahadur, Tiwari Surendra, Shrestha Bimal, Pandit Sanjeet, Sato Fumitaka, Fujita Mitsugu, Sharma Mukunda, Tsunoda Ikuo, Mishra Shravan Kumar
National Public Health Laboratory (NPHL), Department of Health Services, Ministry of Health and Population, Teku, Kathmandu 44-600, Nepal.
Department of Microbiology, Kindai University Faculty of Medicine, Osakasayama, Osaka 589-8511, Japan.
Pathophysiology. 2020 Dec;27(1):3-13. doi: 10.3390/pathophysiology27010002. Epub 2020 Nov 19.
Hepatitis B virus (HBV) infects the liver, causing cirrhosis and cancer. In developed countries, five international guidelines have been used to make a decision for the management of patients with chronic HBV infection. In this review, since the guidelines were established by clinical and epidemiological data of developed countries, we aimed to evaluate whether (1) HBV patient profiles of developing countries are similar to developed countries, and (2) which guideline can be applicable to resource-limited developing countries. First, as an example of the most recent data of HBV infections among developing countries, we evaluated the national HBV viral load study in Nepal, which were compared with the data from other developing countries. In Nepal, the highest number of patients had viral loads of 20-2000 IU/mL (36.7%) and belonged to the age group of 21-30 years; HBV epidemiology in Nepal, based on the viral loads, gender, and age groups was similar to those of not only other developing countries but also developed countries. Next, we reviewed five international HBV treatment guidelines of the World Health Organization (WHO), American Association for the Study of Liver Diseases (AASLD), National Institute for Health and Care Excellence (NICE), European Association for the Study of the Liver (EASL), and Asian Pacific Association for the Study of the Liver (APASL). All guidelines require the viral load and alanine aminotransferase (ALT) levels for decision making. Although four guidelines recommend elastography to assess liver cirrhosis, the WHO guideline alternatively recommends using the aspartate aminotransferase (AST)-to-platelet ratio index (APRI), which is inexpensive and conducted routinely in most hospitals. Therefore, in resource-limited developing countries like Nepal, we recommend the WHO guideline for HBV treatment based on the viral load, ALT, and APRI information.
乙型肝炎病毒(HBV)感染肝脏,可导致肝硬化和癌症。在发达国家,已有五项国际指南用于指导慢性HBV感染患者的管理决策。在本综述中,鉴于这些指南是根据发达国家的临床和流行病学数据制定的,我们旨在评估:(1)发展中国家的HBV患者特征是否与发达国家相似;(2)哪项指南适用于资源有限的发展中国家。首先,作为发展中国家HBV感染最新数据的一个例子,我们评估了尼泊尔的全国HBV病毒载量研究,并将其与其他发展中国家的数据进行比较。在尼泊尔,病毒载量为20 - 2000 IU/mL的患者数量最多(36.7%),且属于21 - 30岁年龄组;基于病毒载量、性别和年龄组的尼泊尔HBV流行病学不仅与其他发展中国家相似,也与发达国家相似。接下来,我们回顾了世界卫生组织(WHO)、美国肝病研究协会(AASLD)、英国国家卫生与临床优化研究所(NICE)、欧洲肝脏研究协会(EASL)和亚太肝脏研究协会(APASL)的五项国际HBV治疗指南。所有指南在决策时都需要病毒载量和丙氨酸转氨酶(ALT)水平。虽然有四项指南推荐使用弹性成像来评估肝硬化,但WHO指南则建议使用天冬氨酸转氨酶(AST)与血小板比值指数(APRI),该方法成本较低且大多数医院都能常规开展。因此,在像尼泊尔这样资源有限的发展中国家,我们建议根据病毒载量、ALT和APRI信息采用WHO的HBV治疗指南。